Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001137439-25-000157
Filing Date
2025-03-03
Accepted
2025-03-03 13:51:27
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 4678
  Complete submission text file 0001137439-25-000157.txt   6445
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Subject) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92271 | Film No.: 25696483
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 8567 HUMMINGBIRD COMMERCE TOWNSHIP MI 48382
Business Address 8 WOLFEBORO RD ETNA NH 03750 734-770-0040
Dauntless Investment Group, LLC (Filed by) CIK: 0002044285 (see all company filings)

EIN.: 994741394 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G